The FDA has approved AstraZeneca's Imfinzi with gemcitabine and cisplatin as neoadjuvant treatment in adults with MIBC.

Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

The promotional effort from Ferring features bladder cancer survivors sharing the news of a new treatment option.

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...

Leveraging the power of AI and machine learning technologies, researchers at Weill Cornell Medicine developed a more ...

In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive ...

AstraZenecas drug Imfinzi (NASDAQ: AZN) has received U.S. approval to treat adult patients with muscle-invasive bladder ...

However, other types of bladder cancer, such as adenocarcinoma, squamous cell carcinoma, and small cell carcinoma, spread much faster. In most cases, treatment started early enough can prevent the ...

"We want to identify the right treatment for the right patient at ... Faltas is a physician-scientist with expertise in bladder cancer biology. They turned to data from the SWOG Cancer Research ...

The FDA has approved Imfinzi (durvalumab) as neoadjuvant and adjuvant treatment in patients with muscle-invasive bladder cancer.

The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in ...